Atrial fibrosis is a major arrhythmogenic substrate in atrial fibrillation (AF), but its non-invasive identification remains limited. We aimed to characterize the plasma lipidomic signature of atrial fibrosis in patients with AF and to develop an integrated predictive model combining lipidomic and clinical features.